Powered by science,
driven by impact.
Our mission is to fully understand the molecular behavior of cancer cells, so they can be rationally targeted and specifically eliminated.
To achieve this, we have assembled a multi-disciplinary team of scientists, computational biologists and clinicians. Together, we have decades of experience at leading institutions across clinical oncology, drug development, genomics, and technology.
Our leadership
Edward Larkin
Chief Executive Officer
Edward is the founder and CEO of Valius. He built the healthcare business at Palantir Technologies and led investments into public & private life sciences companies at Dragoneer Investment Group. Edward received a BS summa cum laude from the University of Notre Dame, an MS from the London School of Economics, and completed a year of the MD program at the University of Pennsylvania School of Medicine.
Claire Oldfield, PhD
Chief Operating Officer
Claire is co-founder and COO. Prior to Valius, she was an Associate Partner at Bain & Company in San Francisco. At Bain, Claire was a leader in the healthcare & life sciences practice, advising major biopharma companies on initiatives across clinical development, market access, and commercial execution. She received her PhD in neuroscience from UC Berkeley, and a BS/MS from ENS Paris.
Sarah Hesse, PhD
Head of Translational Science
Sarah is co-founder and Head of Translational Science. Prior to Valius, she led immuno-oncology translational science teams at Takeda. Prior to Takeda, Sarah was a computational biologist at Intellia Therapeutics. Sarah received her PhD in bioengineering from MIT, where she focused on cytokine signaling and systems immunology in Doug Lauffenburger’s lab. She received her BS in chemical engineering from Johns Hopkins.
Yannis Valtis, MD
Memorial Sloan Kettering Cancer Center
James Lee, MD
University of California,
San Francisco
Santosh Kesari, MD, PhD
Asthra Health & Lundquist Institute
Ansuman Satpathy, MD, PhD
Stanford University
We're hiring.
Our team combines scientific excellence with the clarity of purpose that comes from working directly with patients. If you appreciate both startup speed and clinical rigor, we’d love to talk.
